$NBIX
NEUROCRINE BIOSCIENCES INC Stock $nbix

$nbix Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000091447523000073 Filed on October 31, 2023

Income Statement

Concept	2023 Q4	2023 Q3
Revenue	$515.2M	$498.8M
YoY Change	25.05%	28.59%
Cost Of Revenue	$8.500M	$11.20M
YoY Change	10.39%	83.61%
Gross Profit	$506.7M	$487.6M
YoY Change	25.33%	27.71%
Gross Profit Margin	98.35%	97.75%
Selling, General & Admin	$218.9M	$204.2M
YoY Change	19.68%	9.61%
% of Gross Profit	43.2%	41.88%
Research & Development	$137.5M	$142.2M
YoY Change	16.53%	32.03%
% of Gross Profit	27.14%	29.16%
Depreciation & Amortization	$5.700M	$5.500M
YoY Change	29.55%	37.5%
% of Gross Profit	1.12%	1.13%
Operating Expenses	$356.4M	$346.4M
YoY Change	18.44%	17.82%
Operating Profit	$150.3M	$141.2M
YoY Change	45.36%	60.82%
Interest Expense	$47.90M	$1.100M
YoY Change	230.34%	-8.33%
% of Operating Profit	31.87%	0.78%
Other Income/Expense, Net		-$25.60M
YoY Change		-353.47%
Pretax Income	$198.2M	$115.6M
YoY Change	68.11%	18.08%
Income Tax	$50.50M	$32.50M
% Of Pretax Income	25.48%	28.11%
Net Earnings	$147.7M	$83.10M
YoY Change	65.96%	21.31%
Net Earnings / Revenue	28.67%	16.66%
Basic Earnings Per Share		$0.85
Diluted Earnings Per Share	$1.44	$0.82
COMMON SHARES
Basic Shares Outstanding	98.25M shares	97.65M shares
Diluted Shares Outstanding		101.1M shares

Balance Sheet

Concept	2023 Q4	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.032B	$1.095B
YoY Change	4.28%	36.99%
Cash & Equivalents	$251.1M	$293.7M
Short-Term Investments	$780.5M	$801.4M
Other Short-Term Assets	$97.80M	$108.2M
YoY Change	23.64%	59.35%
Inventory	$38.30M	$28.80M
Prepaid Expenses
Receivables	$439.3M	$417.8M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$1.607B	$1.650B
YoY Change	10.56%	36.86%
LONG-TERM ASSETS
Property, Plant & Equipment	$70.80M	$68.80M
YoY Change	20.82%	12.97%
Goodwill	$5.800M	$5.500M
YoY Change	7.41%
Intangibles	$35.50M	$34.90M
YoY Change	-4.57%
Long-Term Investments	$849.4M	$587.5M
YoY Change	111.56%	28.42%
Other Assets	$49.60M	$43.10M
YoY Change	98.4%	310.48%
Total Long-Term Assets	$1.644B	$1.198B
YoY Change	79.68%	27.76%
TOTAL ASSETS
Total Short-Term Assets	$1.607B	$1.650B
Total Long-Term Assets	$1.644B	$1.198B
Total Assets	$3.251B	$2.848B
YoY Change	37.27%	32.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$318.3M	$394.9M
YoY Change	-8.43%	32.61%
Accrued Expenses	$162.5M	$125.9M
YoY Change	833.91%	627.75%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change		-100.0%
Long-Term Debt Due	$170.1M	$169.9M
YoY Change	0.41%	0.41%
Total Short-Term Liabilities	$654.8M	$691.6M
YoY Change	21.78%	42.57%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$106.3M	$68.60M
YoY Change	257.91%	301.17%
Total Long-Term Liabilities	$106.3M	$68.60M
YoY Change	257.91%	301.17%
TOTAL LIABILITIES
Total Short-Term Liabilities	$654.8M	$691.6M
Total Long-Term Liabilities	$106.3M	$68.60M
Total Liabilities	$1.019B	$846.1M
YoY Change	54.24%	41.3%
SHAREHOLDERS EQUITY
Retained Earnings	-$157.1M	-$304.8M
YoY Change	-61.38%	-38.52%
Common Stock	$2.382B	$2.309B
YoY Change	12.23%	12.37%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.232B	$2.002B
YoY Change
Total Liabilities & Shareholders Equity	$3.251B	$2.848B
YoY Change	37.27%	32.88%

Cashflow Statement

Concept	2023 Q4	2023 Q3
OPERATING ACTIVITIES
Net Income	$147.7M	$83.10M
YoY Change	65.96%	21.31%
Depreciation, Depletion And Amortization	$5.700M	$5.500M
YoY Change	29.55%	37.5%
Cash From Operating Activities	$123.5M	$212.0M
YoY Change	-13.64%	114.57%
INVESTING ACTIVITIES
Capital Expenditures	$5.400M	$7.600M
YoY Change	200.0%	347.06%
Acquisitions
YoY Change
Other Investing Activities	-$196.4M	-$89.70M
YoY Change	72.58%	42.38%
Cash From Investing Activities	-$201.8M	-$97.30M
YoY Change	74.57%	58.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	35.40M	18.80M
YoY Change	43.9%	64.91%
NET CHANGE
Cash From Operating Activities	123.5M	212.0M
Cash From Investing Activities	-201.8M	-97.30M
Cash From Financing Activities	35.40M	18.80M
Net Change In Cash	-42.90M	133.5M
YoY Change	-182.5%	173.01%
FREE CASH FLOW
Cash From Operating Activities	$123.5M	$212.0M
Capital Expenditures	$5.400M	$7.600M
Free Cash Flow	$118.1M	$204.4M
YoY Change	-16.36%	110.5%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q4	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2023#AccountingStandardsUpdate202006Member
	us-gaap	Interest Expense InterestExpense	6000000.0	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-600000	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	23600000	usd
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-70000000.0	usd
CY2023Q3	nbix	Investment Income And Other Net InvestmentIncomeAndOtherNet	15600000	usd
CY2022Q3	nbix	Investment Income And Other Net InvestmentIncomeAndOtherNet	200000	usd
	nbix	Investment Income And Other Net InvestmentIncomeAndOtherNet	37400000	usd
	nbix	Investment Income And Other Net InvestmentIncomeAndOtherNet	2800000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-25600000	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	10100000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	33300000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-49600000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	115600000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	133900000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	96000000.0	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	32500000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	29400000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	31900000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	83100000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	68500000	usd
	us-gaap	Net Income Loss NetIncomeLoss	102000000.0	usd
	us-gaap	Net Income Loss NetIncomeLoss	65500000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	1400000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	0	usd
	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	-700000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	0	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	800000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1800000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	5500000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-12300000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	82500000	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	66700000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	108200000	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.85
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.72
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.05
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.69
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.82
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.69
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.67
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	101100000	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	99000000.0	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	100600000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	98300000	shares
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	2002100000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1374000000	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	23600000	usd
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-77300000	usd
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	5600000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-70000000.0	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-13200000	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	3000000.0	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	67900000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	115700000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-6300000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6500000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	147300000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	77000000.0	usd
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	3800000	usd
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	20700000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	266400000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	196400000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	892700000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	387900000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	681600000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	348800000	usd
	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi	31300000	usd
	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi	7700000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	22900000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14700000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-265300000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-61500000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	29900000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	20100000	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	279000000.0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	29900000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-258900000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	31000000.0	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-124000000.0	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	270700000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	301700000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	220000000.0	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	900000	usd
	us-gaap	Interest Paid Net InterestPaidNet	1900000	usd
	us-gaap	Interest Paid Net InterestPaidNet	4600000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	5000000.0	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	4300000	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	804800000	usd
CY2022Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P13Y7M
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	96500000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	96500000	shares
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	97900000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	30500000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	53200000	usd
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.01
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	97900000	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	95800000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	97500000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	95600000	shares
CY2023Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-600000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	47800000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	18800000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	2002100000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	1423400000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	68500000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1800000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	43100000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	11400000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	1544600000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1707800000	usd
	us-gaap	Net Income Loss NetIncomeLoss	102000000.0	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	6200000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	156200000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	29900000	usd
	us-gaap	Net Income Loss NetIncomeLoss	65500000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-12300000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	129600000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	20100000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	1544600000	usd
	us-gaap	Net Income Loss NetIncomeLoss	102000000.0	usd
	us-gaap	Net Income Loss NetIncomeLoss	65500000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	156200000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	129600000	usd
	us-gaap	Depreciation Depreciation	12900000	usd
	us-gaap	Depreciation Depreciation	11200000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	600000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1000000.0	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2700000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-600000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	344000000.0	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	700000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1800000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2023Q3	nbix	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent	0	usd
CY2023Q3	nbix	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent	3400000	usd
CY2023Q3	nbix	Debt Securities Available For Sale Fair Value Current DebtSecuritiesAvailableForSaleFairValueCurrent	801400000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	735800000	usd
CY2022Q4	nbix	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent	0	usd
CY2022Q4	nbix	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent	9400000	usd
CY2022Q4	nbix	Debt Securities Available For Sale Fair Value Current DebtSecuritiesAvailableForSaleFairValueCurrent	726400000	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	458600000	usd
CY2023Q3	nbix	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Noncurrent AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent	100000	usd
CY2023Q3	nbix	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Noncurrent AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent	4000000.0	usd
CY2023Q3	nbix	Debt Securities Available For Sale Fair Value Noncurrent DebtSecuritiesAvailableForSaleFairValueNoncurrent	454700000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	304500000	usd
CY2022Q4	nbix	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Noncurrent AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent	200000	usd
CY2022Q4	nbix	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Noncurrent AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent	5300000	usd
CY2022Q4	nbix	Debt Securities Available For Sale Fair Value Noncurrent DebtSecuritiesAvailableForSaleFairValueNoncurrent	299400000	usd
CY2023Q3	us-gaap	Interest Receivable Current InterestReceivableCurrent	8100000	usd
CY2022Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	4700000	usd
	us-gaap	Debt Securities Available For Sale Accrued Interest Writeoff DebtSecuritiesAvailableForSaleAccruedInterestWriteoff	0	usd
	us-gaap	Debt Securities Available For Sale Accrued Interest Writeoff DebtSecuritiesAvailableForSaleAccruedInterestWriteoff	0	usd
CY2023Q3	us-gaap	Investments Investments	1690600000	usd
CY2022Q4	us-gaap	Investments Investments	1398600000	usd
CY2023Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	9100000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	12000000.0	usd
CY2023Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	9300000	usd
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	5600000	usd
CY2023Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	10400000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	17500000	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	28800000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	35100000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	212200000	usd
CY2023Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	8000000.0	usd
CY2022Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	7800000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	301700000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	5400000	usd
	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	100000	usd
CY2023Q3	us-gaap	Goodwill Goodwill	5500000	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	34900000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	900000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	3400000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	3400000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	3400000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	3400000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	17000000.0	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	293700000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	220000000.0	usd
CY2023Q3	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	184000000.0	usd
CY2022Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	131900000	usd
CY2023Q3	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	72700000	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	9000000.0	usd
CY2023Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	68600000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	72800000	usd
CY2023Q3	nbix	Accrued Branded Prescription Drug Fee AccruedBrandedPrescriptionDrugFee	44500000	usd
CY2022Q4	nbix	Accrued Branded Prescription Drug Fee AccruedBrandedPrescriptionDrugFee	27500000	usd
CY2023Q3	nbix	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	39500000	usd
CY2022Q4	nbix	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	39100000	usd
CY2023Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	93800000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	67300000	usd
CY2023Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	503000000.0	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	347600000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	12300000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	12500000	usd
	us-gaap	Sublease Income SubleaseIncome	300000	usd
	us-gaap	Sublease Income SubleaseIncome	0	usd
	nbix	Operating Lease Cost Net OperatingLeaseCostNet	12000000.0	usd
	nbix	Operating Lease Cost Net OperatingLeaseCostNet	12500000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	13400000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	12200000	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y2M12D
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y1M6D
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.054
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.053
	us-gaap	Interest Expense InterestExpense	6000000.0	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	4500000	usd
CY2023Q3	us-gaap	Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear	400000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	18500000	usd
CY2023Q3	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	1700000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	17000000.0	usd
CY2023Q3	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	1700000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	15700000	usd
CY2023Q3	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	1700000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	16000000.0	usd
CY2023Q3	us-gaap	Lessor Operating Lease Payments To Be Received Four Years LessorOperatingLeasePaymentsToBeReceivedFourYears	1700000	usd
CY2023Q3	nbix	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	54400000	usd
CY2023Q3	nbix	Lessor Operating Lease Payment To Be Received After Year Four LessorOperatingLeasePaymentToBeReceivedAfterYearFour	6000000.0	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	126100000	usd
CY2023Q3	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	13200000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	22400000	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	103700000	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	17800000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	85900000	usd
CY2023Q3	nbix	Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced Year One NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearOne	17200000	usd
CY2023Q3	nbix	Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced Year Two NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo	33300000	usd
CY2023Q3	nbix	Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced Year Three NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree	41900000	usd
CY2023Q3	nbix	Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced Year Four NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour	43200000	usd
CY2023Q3	nbix	Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced After Year Four NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedAfterYearFour	436500000	usd
CY2022Q1	nbix	Lessee Operating Lease Option Term To Construct Fifth Building LesseeOperatingLeaseOptionTermToConstructFifthBuilding	P6Y
CY2022Q1	nbix	Rent Abatement Period RentAbatementPeriod	P10M
CY2022Q1	nbix	Lessee Operating Lease Monthly Base Rent Per Square Foot LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot	6	usd
CY2022Q1	nbix	Annual Rent Escalation Percentage AnnualRentEscalationPercentage	0.03
CY2022Q1	nbix	Number Of Renewal Options NumberOfRenewalOptions	2	renewaloption
CY2022Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2023Q3	nbix	Debt Instrument Coupon Interest DebtInstrumentCouponInterest	900000	usd
CY2022Q3	nbix	Debt Instrument Coupon Interest DebtInstrumentCouponInterest	1000000.0	usd
	nbix	Debt Instrument Coupon Interest DebtInstrumentCouponInterest	2900000	usd
	nbix	Debt Instrument Coupon Interest DebtInstrumentCouponInterest	5000000.0	usd
CY2023Q3	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	200000	usd
CY2022Q3	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	200000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	600000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1000000.0	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	1100000	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	1200000	usd
	us-gaap	Interest Expense InterestExpense	3500000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	102000000.0	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	102000000.0	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	65500000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	65500000	usd
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	97900000	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	95800000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	97500000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	95600000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	101100000	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	99000000.0	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	100600000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	98300000	shares
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.85
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.72
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.05
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.69
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.82
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.69
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.67
CY2023Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4400000	shares
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4900000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5200000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5500000	shares

Files In Submission

Name	View Source	Status
0000914475-23-000073-index-headers.html	Edgar Link	pending
0000914475-23-000073-index.html	Edgar Link	pending
0000914475-23-000073.txt	Edgar Link	pending
0000914475-23-000073-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nbix-20230930.htm	Edgar Link	pending
nbix-20230930.xsd	Edgar Link	pending
nbix-20230930_g1.jpg	Edgar Link	pending
q3-2023xexhibit311.htm	Edgar Link	pending
q3-2023xexhibit312.htm	Edgar Link	pending
q3-2023xexhibit32.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
nbix-20230930_cal.xml	Edgar Link	unprocessable
nbix-20230930_def.xml	Edgar Link	unprocessable
nbix-20230930_lab.xml	Edgar Link	unprocessable
nbix-20230930_pre.xml	Edgar Link	unprocessable
nbix-20230930_htm.xml	Edgar Link	completed
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NBIX
NEUROCRINE BIOSCIENCES INC Stock $nbix

2023 Q4 Form 10-Q Financial Statement

#000091447523000073 Filed on October 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NBIX NEUROCRINE BIOSCIENCES INC Stock $nbix

2023 Q4 Form 10-Q Financial Statement

#000091447523000073 Filed on October 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NBIX
NEUROCRINE BIOSCIENCES INC Stock $nbix